Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Private label insole and pillow OEM Indonesia

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Orthopedic pillow OEM development factory Taiwan

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.One-stop OEM/ODM solution provider China

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Indonesia custom insole OEM supplier

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Graphene-infused pillow ODM Indonesia

Researchers at the University of Galway have created APOLLO, the world’s largest collection of digital microbe models—247,092 in total—to revolutionize our understanding of the human microbiome and its role in health. This unprecedented database will enable scientists to study how microbes interact with the body, accelerating discoveries in diagnostics, treatments, and precision healthcare. Credit: University of Galway Scientists at the University of Galway have created APOLLO, the largest-ever digital microbiome collection, with 247,092 models to revolutionize health research. Researchers at the University of Galway have developed APOLLO, the world’s largest digital collection of microbial models, comprising 247,092 computer-generated representations of bacteria from the human microbiome. This groundbreaking resource aims to advance our understanding of how microbial communities influence health and disease. Focusing on the bacterial microbiome—the diverse populations of bacteria that live in and on the human body—APOLLO provides detailed models of each microbe’s metabolic processes. By enabling scientists to study microbial functions through computational simulations rather than relying solely on complex lab experiments, this database has the potential to accelerate medical discoveries and improve disease research. Spanning multiple continents, age groups and body sites, APOLLO is the most extensive computational model collection of the human microbiome created to date. The research project builds upon the team’s decade-long expertise, from earlier AGORA (hundreds of microbes) and AGORA2 (thousands of microbes) generations. Simulating Real-World Microbiome Communities The team also created 14,451 computer simulations of individual microbiome communities, based on real-life samples, to reveal how microbial metabolism varies by body site, age, and health conditions. The APOLLO simulations also predicted key fecal metabolites linked to Crohn’s disease, Parkinson’s disease, and child undernutrition – insights that could help shape future diagnostic and treatment strategies. Professor Ines Thiele, University of Galway. Credit: University of Galway/Aengus McMahon The work was conducted by a team of scientists at University of Galway’s Digital Metabolic Twin Centre, led by Professor Ines Thiele, a principal investigator with APC Microbiome Ireland – Research Ireland centre for the study of microbiological community, hosted by University College Cork. Professor Thiele’s research team uses computational modeling to advance precision health. How APOLLO will benefit society: Improved diagnostics – by identifying microbial metabolic markers, APOLLO could help develop non-invasive diagnostic tools, allowing earlier and more accurate diagnosis. Personalized treatments – simulations can predict how an individual’s microbiome interacts with their diet, medications, and health conditions. This could lead to tailored treatments that optimize gut health and improve responses to therapies. Drug development and probiotics – it may be possible to design targeted probiotics, prebiotics, and microbiome-based therapies to treat specific diseases more effectively. Public Health insights – by including diverse microbiomes, APOLLO provides a global perspective, helping address how modern lifestyles impact microbiome health. This knowledge shall guide public health policies, such as around antibiotic use, diet, and disease prevention. Expert Perspectives on APOLLO’s Significance Dr Cyrille Thinnes, project scientist, said: “APOLLO marks a major milestone in personalized microbiome modeling on a global scale. Our microbiome plays crucial roles in digestion, immune function, and overall health. Studying these microbes is essential for understanding how they influence various conditions, from gut health to neurological diseases, and for developing new diagnostic tools, treatments, and personalize healthcare solutions. “APOLLO captures an unprecedented diversity of microbes across continents, demographics, and body sites, filling critical gaps in global health research. It addresses pressing concerns about the impact of westernized lifestyles, characterized by sedentary habits, processed diets, and antibiotic overuse, on microbial diversity and functions. By including understudied non-westernized populations and body sites beyond the gut, APOLLO provides a vital resource for advancing microbiome research and its applications.” Professor Ines Thiele, study lead on the project, said: “The human microbiome is a vital player in health and disease, dynamically interacting with its host. Understanding these complex interactions requires cutting-edge technology. Our research integrates digital models of both microbes and humans, enabling us to explore the microbiome’s role in health in unprecedented detail. “APOLLO takes this innovation further by incorporating microbiome communities on a dimension to now enable personalization on a global scale. “Over the past decade, we have gone from a single generic human model to detailed models that account for sex, physiology, and individual organs. Similarly, we started with models of a few microbes and have now expanded to cover hundreds of thousands. These models can further incorporate information on dietary habits and health conditions, helping to generate testable hypotheses and personalized health recommendations. APOLLO represents a major step in the shift towards digital twin-enabled precision healthcare, moving us closer to tailoring health solutions for individuals worldwide.” Reference: “A genome-scale metabolic reconstruction resource of 247,092 diverse human microbes spanning multiple continents, age groups, and body sites” by Almut Heinken, Timothy Otto Hulshof, Bram Nap, Filippo Martinelli, Arianna Basile, Amy O’Brolchain, Neil Francis O’Sullivan, Celine Gallagher, Eimer Magee, Francesca McDonagh, Ian Lalor, Maeve Bergin, Phoebe Evans, Rachel Daly, Ronan Farrell, Rose Mary Delaney, Saoirse Hill, Saoirse Roisin McAuliffe, Trevor Kilgannon, Ronan M.T. Fleming, Cyrille C. Thinnes and Ines Thiele, 12 February 2025, Cell Systems. DOI: 10.1016/j.cels.2025.101196

A team of Australian researchers discovered a mutation in E. coli that enables it to cause severe infections by preventing cellulose production, offering new insights into combating antibiotic-resistant bacteria. Mutation in E. coli facilitates severe disease by hindering cellulose production, revealing new approaches to fight antibiotic resistance. Queensland researchers have discovered that a mutation allows some E. coli bacteria to cause severe disease in people while other bacteria are harmless, a finding that could help to combat antibiotic resistance. Professor Mark Schembri and Dr. Nhu Nguyen from The University of Queensland’s Institute for Molecular Bioscience and Associate Professor Sumaira Hasnain from Mater Research found the mutation in the cellulose-making machinery of E. coli bacteria. Professor Schembri said the mutation gives the affected E. coli bacteria the green light to spread further into the body and infect more organs, such as the liver, spleen, and brain. “Bad’ bacteria can’t make cellulose “Our discovery explains why some E. coli bacteria can cause life-threatening sepsis, neonatal meningitis, and urinary tract infections (UTIs), while other E. coli bacteria can live in our bodies without causing harm,” Professor Schembri said. “The ‘good’ bacteria make cellulose and ‘bad’ bacteria can’t.” Bacteria produce many substances on their cell surfaces that can stimulate or dampen the immune system of the host. Plants, algae and ‘good’ bacteria make the carbohydrate cellulose, ‘bad’ bacteria can’t. Inflammation and spreading through the body “The mutations we identified stopped the E. coli making the cell-surface carbohydrate cellulose and this led to increased inflammation in the intestinal tract of the host,” Professor Schembri said. “The result was a breakdown of the intestinal barrier, so the bacteria could spread through the body.” In models that replicate human disease, the team showed that the inability to produce cellulose made the bacteria more virulent, so it caused more severe disease, including infection of the brain in meningitis and the bladder in UTIs. E. coli is the most dominant pathogen associated with bacterial antibiotic resistance. Finding new ways to prevent infection Associate Professor Hasnain said understanding how bacteria spread from intestinal reservoirs to the rest of the body was important in preventing infections. “Our finding helps explain why certain types of E. coli become more dangerous and provides an explanation for the emergence of different types of highly virulent and invasive bacteria,” she said. Professor Schembri said E. coli was the most dominant pathogen associated with bacterial antibiotic resistance. “In 2019 alone, almost 5 million deaths worldwide were associated with bacterial antibiotic resistance, with E. coli causing more than 800,000 of these deaths,” he said. “As the threat of superbugs that are resistant to all available antibiotics increases worldwide, finding new ways to prevent this infection pathway is critical to reduce the number of human infections.” Reference: “A convergent evolutionary pathway attenuating cellulose production drives enhanced virulence of some bacteria” by Nguyen Thi Khanh Nhu, M. Arifur Rahman, Kelvin G. K. Goh, Seung Jae Kim, Minh-Duy Phan, Kate M. Peters, Laura Alvarez-Fraga, Steven J. Hancock, Chitra Ravi, Timothy J. Kidd, Matthew J. Sullivan, Katharine M. Irvine, Scott A. Beatson, Matthew J. Sweet, Adam D. Irwin, Jana Vukovic, Glen C. Ulett, Sumaira Z. Hasnain and Mark A. Schembri, 21 February 2024, Nature Communications. DOI: 10.1038/s41467-024-45176-4 The collaboration included teams from UQ’s School of Biomedical Sciences led by Associate Professor Jana Vukovic and from Griffith University’s School of Pharmacy and Medical Sciences led by Professor Glen Ulett.

New research has uncovered the mechanism by which amino acids activate TORC1, a key protein in cell growth and autophagy. The research reveals that cysteine activates TORC1 via the Pib2 protein and highlights the varied influences of all 20 amino acids on TORC1 through two pathways. This discovery offers new insights into cellular processes and potential treatments for diseases linked to TORC1 malfunctions. Researchers at Osaka University uncover the mechanism by which cysteine activates a crucial regulator of cell growth in yeast. Amino acids serve as life’s fundamental components. They are sourced from our diet, and our bodies utilize them to create proteins. These proteins are crucial for growth, development, and various other processes. Yet, prior to utilizing these building blocks, the body must first detect their presence. When amino acids are available, a master regulator protein called TORC1 is switched on, causing proteins to be manufactured and cells to grow. If no amino acids are available, TORC1 is switched off, and cells start to recycle themselves in a process known as autophagy. Until now, it was unclear exactly how amino acids triggered the TORC1 switch in yeast. Discovery in Amino Acid Sensing Now, in a study published in Cell Reports, researchers from Osaka University have revealed how TORC1 is activated: detection of the amino acid cysteine. “We investigated the relationships between amino acids and TORC1 activation in the yeast Saccharomyces cerevisiae,” says the study’s lead author Qingzhong Zeng. “We found that cysteine is sensed by a protein called Pib2 and that the two bind together and activates TORC1. This stimulates the synthesis of proteins and lipids, promoting cell proliferation.” Pib2 senses Cysteine to activate TORC1. Credit: 2023 Noda et al., Pib2 is a cysteine sensor involved in TORC1 activation in Saccharomyces cerevisiae. Cell Reports The Role of Amino Acids in TORC1 Activation What’s more, cysteine is not the only amino acid that triggers TORC1. All 20 amino acids were found to differently affect TORC1 using two ‘pathways’: Pib2 and Gtr. A pathway can be thought of as a specific chain reaction that leads to certain outcomes in a cell. The team set out to elucidate how each amino acid uses these pathways to affect TORC1. “Some amino acids primarily use the Pib2 pathway, while others primarily use Gtr,” explains senior author Takeshi Noda. “We also identified amino acids that can use either pathway and some that need both. This work excites us because it deepens our understanding of how amino acids control cell growth and autophagy, and how each amino acid is detected.” In humans, faulty TORC1 function has been linked to diseases like cancer, diabetes, and dementia. A fuller understanding of how TORC1 is switched on and off, and how each amino acid is detected, could help researchers find new treatments for these diseases – an exciting prospect indeed. Reference: “Pib2 is a cysteine sensor involved in TORC1 activation in Saccharomyces cerevisiae” by Qingzhong Zeng, Yasuhiro Araki and Takeshi Noda, 20 December 2023, Cell Reports. DOI: 10.1016/j.celrep.2023.113599

DVDV1551RTWW78V